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Background: LL-37 is a naturally occurring antimicrobial peptide found in the wound bed and assists wound
repair. No published study has characterized the role of LL-37 in the function(s) of human mesenchymal stem cells
(MSCs). This study investigated the functions of adipose-derived stromal/stem cells (ASCs) activated by LL-37 by
performing both in vitro assays with cultured cells and in vivo assays with C57BL/6 mice with hair loss.
Methods: Human ASCs were isolated from healthy donors with written informed consent. To examine the effects
of LL-37 on ASC function, cell proliferation and migration were measured by a cell counting kit (CCK-8) and a
Transwell migration assay. Early growth response 1 (EGR1) mRNA expression was determined by microarray and
real-time PCR analyses. The protein levels of EGR1 and regenerative factors were analyzed by specific enzyme-linked
immunosorbent assays and western blotting.
Results: LL-37 treatment enhanced the proliferation and migration of human ASCs expressing formyl peptide
receptor like-1. Microarray and real-time PCR data showed that EGR1 expression was rapidly and significantly
increased by LL-37 treatment. LL-37 treatment also enhanced the production of EGR1. Moreover, small interfering
RNA-mediated knockdown of EGR1 inhibited LL-37-enhanced ASC proliferation and migration. Activation of
mitogen-activated protein kinases (MAPKs) was essential not only for LL-37-enhanced ASC proliferation and
migration but also EGR1 expression; treatment with a specific inhibitor of extracellular signal-regulated kinase, p38,
or c-Jun N-terminal kinase blocked the stimulatory effect of LL-37. EGR1 has a strong paracrine capability and can
influence angiogenic factors in ASCs; therefore, we evaluated the secretion levels of vascular endothelial growth
factor, thymosin beta-4, monocyte chemoattractant protein-1, and stromal cell-derived factor-1. LL-37 treatment
increased the secretion of these regenerative factors. Moreover, treatment with the conditioned medium of ASCs
pre-activated with LL-37 strongly promoted hair growth in vivo.
Conclusions: These findings show that LL-37 increases EGR1 expression and MAPK activation, and that
preconditioning of ASCs with LL-37 has a strong potential to promote hair growth in vivo. This study correlates
LL-37 with MSC functions (specifically those of ASCs), including cell expansion, cell migration, and paracrine actions,
which may be useful in terms of implantation for tissue regeneration.
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Cell therapy using adult multipotent stromal cells or
mesenchymal stem cells (MSCs) is clinically used to re-
pair and regenerate various damaged tissues [1, 2].
Adipose-derived stromal/stem cells (ASCs) are multipo-
tent mesenchymal cells isolated from adipose tissue and
are accessible, abundant, and self-replenishing [3]. These
cells are also capable of differentiating into multiple
mesenchymal lineages, including osteoblasts, adipocytes,
chondrocytes, and other types of cells. The differenti-
ation, proliferation, and direct migration of MSCs into
local damaged tissue undergoing regeneration are
regarded as the primary mechanisms underlying the ac-
tions of MSCs [3, 4]. Besides these actions, the strong
paracrine effects of various growth factors and cytokines
secreted by MSCs is a key mechanism underlying MSC-
mediated tissue regeneration and repair [5, 6]. Therefore,
it is important to understand the molecular mechanism
controlling the machinery that underlies these strong
paracrine effects in MSCs.
Early growth response 1 (EGR1), a member of the
immediate-early gene family, encodes a zinc finger tran-
scription factor and is rapidly induced by mitogens and
growth factors [7]. Once induced, EGR1 plays a pivotal
role in the expression and production of various growth
factors, cytokines, and other bioactive molecules, result-
ing in the stimulation of cellular functions for tissue re-
pair and regeneration. Interestingly, EGR1 might be an
activation marker of human MSCs, which highly express
the EGR1 gene, and have multiple roles involving
angiogenesis and mitogenesis [8, 9]. Strong induction of
EGR1 is mediated by the mitogen-activated protein
kinase (MAPK) pathway, a crucial signaling pathway
associated with cell migration and proliferation [7, 10].
LL-37 is a naturally occurring 37-amino acid sequence
synthesized from the C-terminus of human cationic
antimicrobial protein 18 (hCAP-18) [11] and is widely
found in various body fluids and cell types including epi-
thelial cells and immune cells [12, 13]. Secretion of LL-
37/hCAP-18 is significantly elevated at the wound bed,
where this peptide demonstrates proliferative, angio-
genic, and immunomodulatory activities through the
MAPK pathway [14]. Besides participating in innate host
defense [11, 15], this peptide also has wound-healing ef-
fects [16, 17] and is a potent chemoattractant for various
cell types including immune cells through activation of
formyl peptide receptor like-1 (FPRL1), its main receptor
[18]. A recent study by Krasnodembskaya et al. showed
that human MSCs possess direct antimicrobial activity,
which is mediated in part by secretion of the human
cathelicidin hCAP-18/LL-37 [19].
Many studies reported ASC-mediated tissue regeneration
in various damaged tissues [1, 20] and LL-37 is an import-
ant mediator of the repair and regeneration of wounds,bones, islets, and other damaged tissues [16, 21, 22]. How-
ever, the precise effect of LL-37 on adjacent human ASCs
has not been identified. In the present study, we hypothe-
sized that LL-37 enhances their therapeutic potential by ac-
tivating ASCs via EGR1 and MAPK signaling. Our findings
indicate that LL-37 may be used as a preconditioning agent
before ASC transplantation for tissue regeneration.
Methods
Cell culture
Subcutaneous adipose tissue was obtained during elective
surgeries with written informed consent, as approved by
the Samsung Medical Center Institutional Review Board.
All donors were < 40 years old and did not have diabetes
or acute inflammation. The mean body mass index of the
donors was 25.2 ± 3.64. Human ASCs were isolated
according to a previous protocol [23] and cultured in low-
glucose Dulbecco’s modified Eagle’s medium supple-
mented with 10 % fetal bovine serum, 100 U/mL penicil-
lin, and 100 μg/mL streptomycin at 37 °C in a humidified
atmosphere containing 5 % CO2. ASCs were characterized
by the presence of the cell surface markers CD73, CD90,
and CD105 and the absence of CD11b, CD34, CD45, and
HLA-DR [24].
Cell viability and proliferation assays
Cells were treated with human LL-37 (Phoenix Pharma-
ceuticals, USA) for 48 hr under serum deprivation con-
ditions. Cell viability was determined by Trypan blue
staining. Cell proliferation was measured with the cell
counting kit (CCK)-8 according to the manufacturer’s
protocol (Dojindo, Japan). ASCs (5 × 103 cells/well) were
treated with 2.5–20 μg/mL LL-37 for 24 and 48 hr prior
to adding CCK-8 solution. Absorbance at 450 nm was
determined with a multi-plate reader (Molecular Devices,
CA, USA).
Migration assay
A cell migration assay was performed using Transwell
plates (8 μm pore size; Costar, Corning, NY, USA) ac-
cording to a previous study [25]. Briefly, ASCs were sus-
pended in serum-free medium and 100 μL of the cell
suspension (7 × 105 cells/mL) was added to each upper
well. LL-37 at the indicated concentrations (5, 10, and
20 μg/mL) was placed in the lower wells of a 24-well tis-
sue culture plate. After incubation for 6 hr at 37 °C, cells
that had migrated were stained with 0.15 % crystal violet
and counted in five random microscopy fields using the
Scanscope scanning system (Aperio Scanscope, CA,
USA).
Small interfering RNA transfection
Cells were transfected with EGR1-targeting small inter-
fering RNA (siRNA) (Santa Cruz Biotechnology, USA)
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Lipofectamine RNAi (Invitrogen, CA, USA). Briefly, when
cells reached 60–70 % confluency, siRNA (final concentra-
tion, 100 nM) was combined with Lipofectamine RNAi
and allowed to complex for 20 min. The transfection
mixture was then applied to ASCs and incubated for
6 hr at 37 °C. Subsequently, cells were maintained in
complete medium for 36 hr before being subjected to
the cell migration assay and enzyme-linked immuno-
sorbent assays (ELISAs).
Western blot analysis
Total protein from cell lysates was separated by SDS-
PAGE and transferred to a nitrocellulose membrane, which
was incubated with the corresponding primary antibodies
(anti-EGR1 (Santa Cruz Biotechnology) and anti-GAPDH
(Cell Signaling, USA)) overnight at 4 °C. Washed
membranes were incubated for 1 hr with a horseradish
peroxidase-conjugated anti-mouse secondary antibody.
Bands were visualized using an enhanced chemilumines-
cence detection system (Amersham Biosciences, Piscat-
away, NJ, USA). The band intensities were quantified using
TotalLab software (UK).
Fluorescence-activated cell sorting
FPRL1 expression in ASCs from four donors was evaluated
by surface staining. Cells were washed with fluorescence-
activated cell sorting (FACS) buffer, stained with a mouse
anti-FPRL1 antibody (R&D Systems, USA), and then
stained with anti-mouse IgG-FITC (Sigma, USA). Labeled
cells were measured with a FACSCalibur instrument
(Becton Dickinson Biosciences, CA, USA) and analyzed
using the Win MDI program (Win MDI version 2.8).
Immunostaining
Immunofluorescence analysis was performed as previ-
ously described [23]. Briefly, ASCs (5 × 103 cells/well)
were seeded on four-well Lab-Tek II chamber slides
(Nalge Nunc International, IL, USA), treated with LL-37
for 48 hr, fixed, and permeabilized for 20 min with 0.1 %
Triton X-100 prepared in phosphate-buffered saline.
After washing, cells were blocked and incubated with an
anti-proliferating cell nuclear antigen (PCNA) antibody
(Abcam, Cambridgeshire, UK) for 1 hr. Next, cells were
incubated with goat anti-mouse IgG-Alexa Fluor 488
(Invitrogen) for 30 min at 37 °C. A nucleic acid dye
(DAPI; 0.5 μg/mL) was added to stain the nuclei. PCNA
immunofluorescence was detected with an LSM700 con-
focal microscope system (Carl Zeiss, NY, USA; 400×
objective).
ELISA
Cells were plated in six-well plates (300,000 cells/well)
and treated with 20 μg/mL LL-37 in serum-freemedium. After 48 hr, the culture medium was collected
and ELISAs were performed for thymosin beta-4 (TB4;
Immune Diagnostics, Canada), vascular endothelial
growth factor (VEGF; Invitrogen), monocyte chemo-
attractant protein-1 (MCP-1; eBioscience, USA), stromal
cell-derived factor-1 (SDF-1; RayBiotech, USA), and
EGR1 (EIAab, China), in accordance with the manufac-
turers’ recommendations. For detection of EGR1, the
cells were lysed by the addition of 200 μL of cell lysis
buffer after LL-37 treatment for 6 hr.
Real-time PCR
Total RNA was extracted using TRIzol reagent (Invitro-
gen). After removing possible DNA contamination by
DNAse treatment of the extracted RNA, cDNA was syn-
thesized using 2 μg of total RNA and SuperScript II re-
verse transcriptase according to the manufacturer’s
instructions. The primers used are provided in Additional
file 1: Table S1. For real-time PCR, quantitative PCR
was performed using the 7900 Real-Time PCR System
(Applied Biosystems, Foster City, CA, USA) and the
Power SYBR Green qPCR Master Mix Kit (Life Tech-
nologies, CA, USA). The cycling profile for real-time
PCR (50 cycles) was as follows: 95 °C for 10 min, 95 °C
for 15 sec, and 60 °C for 60 sec. The comparative
threshold cycle (Ct) method (i.e., 2-ΔΔCt) was used to
calculate fold amplification.
Microarray
The microarray data are accessible in the Gene Expres-
sion Omnibus (GEO) database under accession number
GSE76392. For the microarray, human ASCs were
treated with 20 μg/mL LL-37 for 1 hr. Each total RNA
sample (200 ng) was labeled and amplified using the
Low Input Quick Amp Labeling Kit (Agilent Technolo-
gies, CA, USA). Cy3-labeled aRNAs were resuspended
in 100 μL of hybridization solution (Agilent Technologies).
Labeled aRNAs were placed on the Agilent SurePrint G3
Human GE 4x44K array (Agilent Technologies) and cov-
ered with a Gasket 8-plex slide (Agilent Technologies).
Slides were hybridized for 17 hr at 65 °C. The hybridized
slides were sequentially washed in 2× SSC containing
0.1 % SDS for 2 min, 1× SSC for 3 min, and 0.2× SSC for
2 min at room temperature. Finally, the slides were centri-
fuged at 3000 rpm for 20 sec to dry. Arrays were analyzed
using an Agilent scanner with associated software. Gene
expression levels were calculated with Feature Extraction
v10.7.3.1 (Agilent Technologies). The relative signal inten-
sities of each gene were generated using the Robust Multi-
Array Average algorithm. Data were processed based on
the quantile normalization method using GeneSpring GX
13.0 (Agilent Technologies). This normalization method
aims to make the distribution of intensities for each array
in a set of arrays the same. The normalized and log-
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Spring GX 13.0. Fold-change filters included the require-
ment that the genes be present in at least 200 % of
controls for upregulated genes and less than 50 % of con-
trols for downregulated genes. Hierarchical cluster ana-
lysis was conducted using the Cluster 3.0 program, the
Euclidean distance, and average linkage algorithm.Animals and in vivo hair growth test
Five-week-old male C57BL/6 mice were purchased from
SLC Inc. (Haruno, Japan) and allowed to adapt to their
new environment for 2 weeks. The fur on the backs of
7-week-old mice (n = 14) was shaved with hair clippers
and removed with hair removal cream. Conditioned
medium (CM) was topically applied daily for up to
18 days. Pigment darkening and the hair growth rate
were monitored every 3 days for 2 weeks. Hair growth
was evaluated by three independent dermatological sci-
entists. The hair growth score was determined using the
method described by Vegesna et al. [26, 27]. The animal
experiments were approved by the Institutional Animal
Care and Use Committee of Samsung Medical Center
(approval number: SMC-IACUC-2013-0103-003) and all
experiments followed regulatory standards.Plasmid construction and selection of stably transfected
cell lines
hEGR1 was subcloned into the Hind III/Xho I sites of
pcDNA3.1(+). After digestion of the pcDNA3.1(+)-
hEGR1 plasmid with the restriction enzymes, the result-
ing hEGR1 gene along with the BamHI and SfiI sites was
inserted into the multiple cloning site of the expression
plasmid pLenti6/V5-D-TOPO (Invitrogen), which
contains a cytomegalovirus promoter upstream of the
inserted gene. The resulting plasmid was named
pLenti6/V5-hEGR1.
The lentiviral expression system based on four plas-
mids was obtained from Invitrogen. Briefly, 2.5 μg of
pLP1, 2.5 μg of pLP2, 2.5 μg of pLP/VSVG, and 2.5 μg
of the lentiviral vector pLenti6/V5-hCAMP were co-
transfected with Fugene6 (Roche) into HEK293T cells
cultured in 10 cm plates. The medium was changed
every 24 hr. After 48 hr, supernatants were pooled, fil-
tered through a 0.45-μm filter, and centrifuged at
6000 rpm at 4 °C for 16 hr. The pellet was resuspended
in 1 mL of complete medium and stored at −80 °C. The
resulting recombinant lentivirus was added to ASCs cul-
tured in 10 cm plates. At 48 hr after seeding, the
medium was replaced with complete medium containing
10 μg/mL blasticidin as a selective agent. At 18 days
after transfection, selected cell colonies were split into
60 mm petri dishes. Isolated cell colonies were cultured
and expanded.Statistical analysis
Statistical significance was estimated using the Student’s
t-test. Mean differences were considered to be significant
when P < 0.05.
Results
LL-37 increases the proliferation and migration of human
ASCs in a dose-dependent manner
LL-37 reportedly activates functions such as prolifera-
tion and migration through FPRL1, a G-protein-coupled
receptor, in many cell types [18]; therefore, several donor
pools of ASCs were examined for expression of FPRL1.
Flow cytometric data confirmed that FPRL1 was
expressed on ASCs in each donor pool (Fig. 1a).
To investigate the role of LL-37 in ASC proliferation,
we examined the effect of LL-37 on the proliferative
ability of ASCs using the CCK-8 assay. LL-37 treatment
markedly stimulated ASC proliferation in a dose-
dependent manner without causing cytotoxicity (Fig. 1b
and Additional file 2: Figure S1a). Furthermore, we de-
termined the number of proliferating cells by performing
immunofluorescence staining of PCNA, a nuclear pro-
tein associated with cell proliferation. The proportion of
ASCs with positively stained nuclei (green fluorescence)
was markedly enhanced by LL-37 treatment (Fig. 1c).
To investigate the effects of LL-37 on ASC migration,
a Transwell migration assay was performed. LL-37 treat-
ment rapidly increased human ASC migration within
6 hr; this effect was dose-dependent, with maximal
stimulation at 20 μg/mL among the concentrations
tested (Fig. 1d). ASCs were pretreated with pertussis
toxin (Ptx), a Gαi inhibitor, or a neutralizing anti-LL-37
antibody (αLL-37) before activation with LL-37. Ptx or
αLL-37 treatment prior to LL-37 stimulation signifi-
cantly inhibited ASC migration and proliferation (Fig. 1e
and f ). Taken together, these data suggest that LL-37
induces ASC proliferation and migration through the
Gαi-coupled receptor FPRL1.
EGR1 is critical for LL-37-enhanced ASC migration and
proliferation
We investigated the target genes of LL-37 that induce
ASC proliferation and migration using the Agilent hu-
man 4x44K array, a human signaling pathway finder.
Microarray analysis showed that LL-37 treatment signifi-
cantly increased EGR1 expression by 18.47-fold (Table 1
and Additional file 3: Table S2). LL-37 treatment also in-
creased the levels of several genes (including EGR2, early
growth response 2; KLF10, Krupple-like factor 10; FOS;
and CTGF, connective tissue growth factor) linked to
various functions, such as the cell cycle, cell migration,
cell proliferation, and transcription. To confirm the ef-
fect of LL-37 treatment on EGR1 expression in ASCs,
cells were treated with 10 or 20 μg/mL LL-37 for
Fig. 1 Effects of LL-37 on the proliferation and migration of human ASCs. a FPRL1 expression on ASCs from four donors, as analyzed by flow cytometry.
b Proliferating cells were measured at 24 and 48 hr using the CCK-8 assay. A representative experiment of three independent experiments is shown.
Bars represent the mean ± SD. *, P< 0.01 vs. control at 24 or 48 hr. c Immunostaining was performed and visualized using a confocal microscope.
Bar = 100 μm. d ASCs were seeded in the upper wells and the lower wells were treated with 5, 10, and 20 μg/mL LL-37 for 6 hr. A migration assay was
performed using Transwell chambers. Cells that migrated were counted using Scanscope (images show samples treated with 20 μg/mL LL-37). A
representative experiment from three independent experiments is shown. Bars represent the mean ± SEM. *, P < 0.05 vs. control. e ASC proliferation was
analyzed after pretreatment of cells with Ptx or an anti-LL-37 neutralizing antibody (αLL-37) with or without LL-37. f ASC migration was analyzed after
pretreatment of cells with Ptx or αLL-37 prior to LL-37 treatment. Values represent the mean ± SD of three independent experiments. *, P < 0.01 vs.
control; §, P < 0.01 vs. LL-37-treated cells. ASCs adipose-derived stromal/stem cells, FPRL1 formyl peptide receptor like-1, Ptx pertussis toxin
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lysis was performed. LL-37 treatment significantly in-
creased the EGR1 mRNA level, which peaked at 1 hr
and returned to the basal level at about 6 hr (Fig. 2a).
Because LL-37 treatment considerably increased the
mRNA level of EGR1, we attempted to ascertain
whether it also increased the protein level of EGR1 via
western blot analysis. LL-37 treatment rapidly increased
the protein level of EGR1 in ASCs in a time-dependent
manner (Fig. 2b). In addition to western blot analysis,
ELISA analysis of cell lysates demonstrated that EGR1
production was significantly increased by LL-37 treat-
ment (Additional file 2: Figure S1b)
Next, to study the involvement of EGR1 in LL-37-
enhanced ASC proliferation and migration, ASCs were
transfected with EGR1-targeting siRNA. We confirmedEGR1 gene silencing at the protein level (Fig. 2c). LL-37-
enhanced proliferation and migration of ASCs were
markedly attenuated by EGR1-targeting siRNA transfec-
tion (Fig. 2d and e). These data suggest that EGR1 is im-
portant for LL-37-enhanced migration and proliferation
of ASCs.
Involvement of the MAPK pathway in LL-37-induced ASC
proliferation and migration
The MAPK pathway plays an important role in the
migration and proliferation of MSCs and cancer cells
[10, 28]. To elucidate the signaling mechanism involved
in LL-37-induced ASC proliferation and migration in
detail, we examined the effect of LL-37 on the MAPK
pathway in human ASCs. Treatment with LL-37 sig-
nificantly increased the levels of phosphorylated






Early growth response 1 (EGR1) NM_001964 18.47 Transcription, Immune response
Early growth response 2 (EGR2) NM_000399 6.13 Transcription
High mobility group AT-hook 2 (HMGA2) NM_003483 4.72 Transcription
Response gene to complement 32 (RGC32) NM_014059 4.33 Cell cycle
Solute carrier family 20 (phosphate transporter) (SLC20A1) NM_005415 4.19 Signal transduction
Dual specificity phosphatase 1 (DUSP1) NM_004417 3.94 Cell cycle
Dual specificity phosphatase 6 (DUSP6) NM_001946 3.74 Cell cycle, Signal transduction
Connective tissue growth factor (CTGF) NM_001901 3.71 Cell migration, Cell growth, Cell adhesion, Signal
transduction
Kruppel-like factor 10 (KLF10) NM_005655 3.31 Transcription, Signal transduction, Cell proliferation
Dachsous 1 (Drosophila) (DCHS1) NM_003737 3.05 Cell adhesion
Tumor necrosis factor receptor superfamily, member 12A
(TNFRSF12A)
NM_016639 2.98 Apoptosis, Cell adhesion
Pleckstrin homology-like domain, family A, member 2 (PHLDA2) NM_003311 2.94 Apoptosis
v-fos FBJ murine osteosarcoma viral oncogene homolog (FOS) NM_005252 2.80 Transcription, Inflammatory response, Immune
response
Tribbles homolog 2 (Drosophila) (TRIB2) NM_021643 2.56 Cell adhesion
Tubulin, beta 2C (TUBB2C) NM_006088 2.52 Transport, Apoptosis
Ras association (RalGDS/AF-6) and pleckstrin homology domains 1
(RAPH1)
NM_213589 2.46 Signal transduction
Myeloid cell leukemia sequence 1 (BCL2-related) (MCL1) NM_021960 2.34 Apoptosis
SH2B adaptor protein 3 (SH2B3) NM_005475 2.26 Cell cycle, Signal transduction
Cysteine-rich, angiogenic inducer, 61 (CYR61) NM_001554 2.19 Cell adhesion, Cell proliferation
Sphingosine kinase 1 (SPHK1) NM_021972 2.10 Cell migration, Apoptosis, Cell cycle, Cell
proliferation
Ras association (RalGDS/AF-6) and pleckstrin homology domains 1
(RAPH1)
NM_213589 2.01 Signal transduction
The fold increase indicates the increase in expression in comparison to control cells, as determined by a human cDNA microarray
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c-Jun N-terminal kinase (JNK), but did not change the
total levels of these proteins (Fig. 3a). To further deter-
mine the involvement of kinase phosphorylation in the
increased migration, proliferation, and EGR1 production
of ASCs, cells were treated with LL-37 in the presence
and absence of a specific inhibitor of ERK (PD98059),
p38 (SB203580), or JNK (SP600125). All these MAPK
inhibitors (PD98059, SB203580, and SP600125) signifi-
cantly reduced LL-37-induced EGR1 production (Fig. 3b).
In addition, each of the inhibitors attenuated the LL-37-
induced increase in ASC migration and proliferation
(Fig. 3c and d). Taken together, these data suggest that:
1) LL-37 induces multiple signaling pathways, including
those linked with ERK, p38, and JNK phosphorylation;
and 2) these kinases are involved in the regulation of
human ASC migration and proliferation. These results
suggest that LL-37 stimulates ASC function through a
MAPK-dependent mechanism.LL-37 treatment enhances growth factor production in
human ASCs, and treatment with the CM of ASCs
pre-activated with LL-37 stimulates hair regeneration in vivo
It was recently reported that EGR1 has a strong para-
crine capability and can influence angiogenic factors in
ASCs [8, 29]; therefore, we first examined whether LL-
37 regulates the expression of various regenerative
growth factors and bioactive molecules in ASCs. LL-37
treatment considerably upregulated the mRNA expres-
sion of VEGF, TB4, MCP-1, and SDF-1 (Fig. 4a–d). We
next confirmed the direct secretion of these growth
factors by ASCs using ELISAs. The secretion levels of
VEGF, TB4, MCP-1, and SDF-1 were significantly
increased by LL-37 treatment (Fig. 4e–h).
To further evaluate the paracrine effects of LL-37
in vivo, the hair growth of C57BL/6 mice with hair loss
was tested in vivo. We compared hair growth after top-
ically applying CM of ASCs pre-activated with or with-
out LL-37 (20 μg/mL). After 2 weeks, the hair growth
Fig. 2 EGR1 is critical for human LL-37-enhanced ASC migration and proliferation. a EGR1 mRNA expression was determined by real-time PCR.
EGR1 mRNA was detected after treatment with 10 and 20 μg/mL LL-37 for 0–6 hr. b ASCs were incubated with 20 μg/mL LL-37 for 0–6 hr. Cell
lysates were collected for western blot analysis. The EGR1 protein level was increased by LL-37 treatment in a time-dependent manner. c ASCs
were treated with LL-37 and transfected with siRNA targeting EGR1 or a negative control sequence. After stabilization, cells were collected and
lysed by the addition of 200 μL of cell lysis buffer. EGR1-targeting siRNA transfection was quantified by performing an EGR1-specific ELISA of cell
lysates. d Cells that migrated after EGR1-targeting siRNA transfection were imaged by microscopy and counted using Scanscope. Results are
expressed as the mean ± SD of three independent experiments. *, P < 0.01 vs. control; §, P < 0.01 vs. LL-37-treated cells transfected with negative
control siRNA. e The effects on human ASC proliferation were similar to those on migration. A representative experiment from three independent
experiments is shown. Bars represent the mean ± SD. *, P < 0.01 vs. control; §, P < 0.01 vs. LL-37-treated cells transfected with negative
control siRNA. EGR1 early growth response 1, ASC adipose-derived stromal/stem cells, siRNA small interfering RNA, ELISA enzyme-linked
immunosorbent assay
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than in the negative control group treated with medium
alone. Moreover, the hair growth score was higher in the
group treated with CM of ASCs pre-activated with LL-
37 than in the group treated with CM of non-activated
ASCs (Fig. 4i and j), with dark pigmentation and hair re-
generation observed on the initially pink hairless skin.
Treatment with minoxidil (MNX), which is widely used
to treat hair loss, was also effective for hair regeneration.
Specifically, 95–100 % of hair was regenerated to full
length in the group treated with CM of ASCs pre-
activated with LL-37 in comparison to the MNX-treated
group, whereas the level of regeneration was lower in
the group treated with CM of non-activated ASCs (30–
35 %; Fig. 4i). Additionally, to elucidate the biological
function of EGR1 in vitro and in vivo, EGR1 was lentivi-
rally introduced into human ASCs. Cell lines stably ex-
pressing the control vector and EGR1 were designated
pLenti6/V5-D-TOPO and pLenti6/V5-hEGR1, respectively.As expected, the secretion levels of VEGF, TB4, MCP-1,
and SDF-1 were significantly higher in the medium of cells
overexpressing EGR1 than in the medium of wild type
(WT) cells or those expressing the control vector
(Additional file 2: Figure S2a–2d). To confirm the para-
crine effects of stable EGR1-overexpressing cells in vivo,
we performed an additional investigation of hair regener-
ation. Mice were treated with CM of WT ASCs, ASCs
expressing the control vector, or EGR1-overexpressing
ASCs. Compared with CM of WT ASCs and ASCs ex-
pressing the control vector, treatment with CM of
EGR1-overexpressing ASCs considerably increased hair
regeneration (Additional file 2: Figure S2e and 2f ).
Taken together, LL-37 might mediate paracrine actions
by stimulating the secretion of growth factors such as
VEGF, TB4, SDF-1, and MCP-1 by ASCs. In addition,
CM from ASCs pre-activated with LL-37 and EGR1-
overexpressing cells strongly promotes hair growth
in vivo.
Fig. 3 Involvement of the MAPK pathway in LL-37-induced ASC proliferation and migration. a Human ASCs were treated with 20 μg/mL LL-37
for 1, 2, 4, 24, and 48 hr. After cell lysis, the levels of phosphorylated ERK1/2, p38, and JNK were determined by western blot analysis. The levels of
total ERK1/2, p38, and JNK were used to confirm equal loading of the cell lysates. LL-37 treatment significantly increased the phosphorylation of
ERK1/2, p38, and JNK. b ASCs were pretreated with or without a specific inhibitor of ERK1/2 (PD98059), p38 (SB203580), or JNK (SP600125) for 1 hr
and then treated with 20 μg/mL LL-37. EGR1 protein levels in cell lysates were analyzed by an EGR1-specific ELISA. c LL-37-enhanced migration
decreased in human ASCs treated with PD98059, SB203580, or SP600125. d LL-37-enhanced ASC proliferation was inhibited by treatment with
specific inhibitors of ERK1/2, p38, or JNK (similar to ASC migration). A representative experiment from three independent experiments is shown.
Bars represent the mean ± SD. *, P < 0.01 vs. control; §, P < 0.01 vs. LL-37-treated ASCs. MAPK mitogen-activated protein kinase, ASCs adipose-derived
stromal/stem cells, EGR1 early growth response-1
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Many recent studies report clinical trials of ASCs (or
CM from ASCs) for the treatment of vascular injury and
for the promotion of bone, skin, and hair regeneration
[1, 2, 30]. However, the regenerative effects of MSCs are
limited because they vary according to the donor, the
donor’s age, the sampling site, and the culture techniques
and conditions. Therefore, it is essential to develop an
activator of MSCs. LL-37 is a naturally occurring anti-
microbial peptide found in the wound bed, where it as-
sists wound repair and regeneration [15–17]; it is
important to elucidate the relationship between LL-37
and adjacent ASCs for tissue regeneration and repair.
Therefore, we investigated the functions of ASCs acti-
vated by LL-37 exposure.
We demonstrated that human ASCs expressed FPRL1
and that LL-37 treatment significantly enhanced the pro-
liferation and migration of these cells. Next, we searched
for the factor(s) that underlies LL-37-enhanced migrationand proliferation of ASCs. Initially, we thought that TB4
and MCP-1 were candidates for such factors because LL-
37 treatment considerably enhanced their production
(Fig. 4f and h), which facilitated ASC migration (unpub-
lished data). However, these are not the main factors, al-
though this is only one possible mechanism underlying
LL-37-enhanced migration of ASCs. This is because LL-
37 treatment rapidly promoted the migration of human
ASCs within 6 hr (Fig. 1d), whereas TB4 and MCP-1 pro-
duction was noticeably changed much later, after about
24 hr (Fig. 4f and h). Our microarray and real-time PCR
data showed that EGR1 mRNA expression rapidly
responded to LL-37 stimulation within 1 hr (Fig. 2a and
Table 1). Moreover, western blot and ELISA analyses re-
vealed that LL-37 treatment also significantly increased
EGR1 protein levels by about 5–10-fold at 6 hr (Fig. 2b
and Additional file 2: Figure S1b), which regulated ASC
migration (Fig. 2d). Some previous studies reported that
EGR1 mRNA was rapidly induced within 1–2 hr and that
Fig. 4 Preconditioning with LL-37 stimulates hair regeneration in vivo and production of regenerative factors in vitro. a VEGF, (b) TB4, (c) SDF-1α,
and (d) MCP-1 mRNA expression was determined by real-time PCR. e VEGF, (f) TB4, (g) SDF-1α, and (h) MCP-1 proteins were detected using the
supernatants of confluent cell cultures. ASCs were treated with 20 μg/mL LL-37 for 48 hr, and then the protein levels of VEGF, TB4, SDF-1α, and
MCP-1 were analyzed using specific ELISAs. A representative experiment from three independent experiments is shown. Bars represent the mean
± SD. *, P < 0.05 vs. control. i Hair was removed from the backs of C57BL/6 mice and the hair growth rate was monitored for 3 weeks. CM of
human ASCs pretreated with or without LL-37 (20 μg/mL) was topically applied daily for up to 18 days to mice with hair loss. Gross views
observed by photographs. j Hair growth was scored as described in the Materials and methods section. *, P < 0.05 for control vs. group treated
with ASC CM. §, P < 0.05 for group treated with ASC CM vs. group treated with CM of ASCs pre-activated with LL-37. VEGF vascular endothelial
growth factor, TB4 thymosin beta-4, SDF-1α stromal cell-derived factor-1α, MCP-1 monocyte chemoattractant protein-1, ASC adipose-derived
stromal/stem cell, ELISA enzyme-linked immunosorbent assay, CM conditioned medium
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same time [29, 31]. Interestingly, our data showed that
EGR1 protein induction was a little sluggish, although
EGR1 mRNA expression was immediately increased
within 1 hr. However, as in other reports, EGR1 protein
was slowly induced at 5–6 hr [32–34]. It is possible that
the optimal time of EGR1 induction differs according to
the type of stimulus (e.g., cytokine, growth factor, and oxi-
dative stress) or the cell type. A recent study by Min et al.
suggested that EGR1 controls hematopoietic stem cell mi-
gration and expansion [35]. Similarly, our data showedthat EGR1-targeting siRNA transfection inhibited LL-37-
enhanced proliferation and migration of ASCs (Fig. 2c–e).
Thus, these results suggest that EGR1 is important for the
regulation of LL-37-enhanced proliferation and migration
of human ASCs.
In this study, LL-37 promoted the expansion and mi-
gration of human ASCs at all concentrations, but was
most effective at 20 μg/mL (Fig. 1b and d). Interestingly,
EGR1 expression was highest in ASCs treated with a
lower concentration (10 μg/mL) of LL-37 (Fig. 2a), sug-
gesting that, in addition to EGR1, other factors and
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tion and migration of human ASCs. For example, LL-37
treatment also considerably increased interleukin (IL)-8
expression and secretion in human ASCs (Additional file
2: Figure S3a and S3b). We previously demonstrated that
IL-8 induced by TB4 plays a key role in ASC proliferation
[23]. Moreover, IL-8 stimulated ASC migration, and IL-8
knockdown using IL-8-specific siRNA inhibited cell mi-
gration (unpublished data). IL-8 promotes angiogenesis
and migration of bone marrow-derived MSCs [36], and
may also affect multiple functions of human ASCs, includ-
ing their proliferation and migration. Further investiga-
tions are necessary to clarify the other mechanisms
underlying LL-37-induced proliferation and migration of
human ASCs and the factors involved. Taken together,
these data suggest that EGR1 is an important, but not the
only, factor for LL-37-mediated ASC migration and
proliferation.
It was recently reported that EGR1 has a strong para-
crine capability and can influence angiogenic factors in
ASCs [8, 29]; therefore, we investigated the enhanced se-
cretion of TB4, VEGF, MCP-1, and SDF-1 in response to
LL-37 stimulation (Fig. 4a–h). These growth factors and
cytokines are associated with the regeneration and repairFig. 5 Scheme representing the functions of ASCs after LL-37 treatment. LL
pathways. Furthermore, LL-37 stimulates the secretion of growth factors su
preconditioned with LL-37 strongly promotes hair growth in vivo. LL-37 can b
approach for tissue regeneration by enforcing the functions of ASCs (e.g., exp
stem cells, EGR1 early growth response 1, MAPK mitogen-activated protein kin
stromal cell-derived factor-1α, MCP-1 monocyte chemoattractant protein-1, CMof various tissues, including skin, bone, and skeletal
muscle [37–40]. Among them, TB4 directly stimulates
hair growth and proliferation of hair follicle dermal pa-
pilla cells. Furthermore, TB4 accelerates hair growth via
activation, migration, and differentiation of hair follicle
stem cells [38, 41]. Recently, VEGF was shown to stimu-
late hair growth by facilitating the supply of nutrients to
the hair follicle, increasing the follicular diameter [42, 43].
Based on these reports, TB4 and VEGF are regarded as
the main factors in the hair growth promotion effect of
the CM of LL-37-activated ASCs. Interestingly, one of
these regenerative factors, MCP-1, is a pro-inflammatory
cytokine. However, it also promotes healing in diabetic
wounds, dental pulp, and skeletal muscle by increasing
cell migration, angiogenesis, or macrophage infiltration,
leading to a higher regenerative potential [39, 44, 45].
Therefore, MCP-1 seems to be a key cytokine mediating
regenerative effects as well as a pro-inflammatory cyto-
kine, and its action might depend on the microenviron-
ment in the human body. LL-37-enhanced regenerative
factors also influence their microenvironment through
paracrine actions [46]. In support of this, CM from ASCs
pre-activated with LL-37 strongly promoted hair growth
as efficiently as MNX (95–100 % of hair), which is a-37 enhances ASC proliferation and migration via the EGR1 and MAPK
ch as VEGF, TB4, SDF-1, and MCP-1 in human ASCs. CM from ASCs
e modulated to activate human ASCs and may provide a therapeutic
ansion, migration, and paracrine actions). ASCs adipose-derived stromal/
ase, VEGF vascular endothelial growth factor, TB4 thymosin beta-4, SDF-1α
conditioned medium
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j). Besides these paracrine actions, we previously demon-
strated that the SDF-1/CXCR4 axis is essential for human
dermal fibroblast (HDF) migration, resulting in wound-
healing effects [25]. This suggests that CXCR4-expressing
HDFs can migrate along the concentration gradient of
SDF-1 secreted by human ASCs in response to LL-37 at
wound sites, leading to wound repair and regeneration.
Liu et al. and Neuhaus et al. reported that SDF-1 also
enhances EGR1 expression in endothelial cells and
angiogenesis in ischemic regions [47, 48]. Based on
these reports, LL-37-induced SDF-1 might also enhance
EGR1 expression in human ASCs. Therefore, it is rea-
sonable to conclude that LL-37 can gradually accelerate
other mechanisms via autocrine loops and paracrine ac-
tions on adjacent cells such as HDFs. Taken together,
LL-37 may activate human ASCs via autocrine and
paracrine actions.Conclusions
In summary, these results demonstrate that LL-37 en-
hances ASC proliferation and migration via the EGR1
and MAPK pathways (Fig. 5). Furthermore, LL-37 stim-
ulates the secretion of growth factors such as VEGF,
TB4, SDF-1, and MCP-1. CM from ASCs preconditioned
with LL-37 strongly promotes hair growth in vivo. There-
fore, LL-37 can be modulated to activate human ASCs
and may provide a therapeutic approach to tissue regener-
ation by enforcing the functions of ASCs (e.g., expansion,
migration, and paracrine actions).Additional files
Additional file 1: Table S1. List of primers used for real-time PCR.
(PDF 106 kb)
Additional file 2: Figure S1. Effects of LL-37 on the viability and EGR1
production of human ASCs. Figure S2. EGR1-overexpressing ASCs secrete
higher levels of the regenerative factors VEGF, TB4, SDF-1α, and MCP-1,
and the CM of these cells stimulates hair regeneration in vivo. Figure S3.
LL-37 increases the expression and production of IL-8 in human ASCs.
(PDF 267 kb)
Additional file 3: Table S2. List of upregulated genes in ASCs exposed
to LL-37 by microarray analysis. (XLS 45 kb)
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